香港，2017年9月6日 –亚盛医药，一家面向全球进入临床阶段的生物制药公司，今天宣布公司高管将出席于 2017年9月8日星期五在美国纽约千禧百老汇酒店举办的第24届年度NewsMakers生物技术行业大会。当天上午9点（东部时间），公司董事长兼CEO杨大俊博士将在会上发表公司演讲。
HONG KONG, Sep 6th,2017 – Ascentage Pharma, a global clinical-stage biopharmaceutical company, wil attend the 24th Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017 at the Millennium Broadway Hotel in New York City. Dr. Dajun Yang, MD, PhD, Chairman & Chief Executive Officer, will make the scheduled 25-minute presentation at 9:00 a.m. Eastern Time.
同时，包括公司董事长兼CEO杨大俊博士、首席财务官李含中博士以及商业开发副总监张璐在内的亚盛医药管理团队，将于2017年9月11日至13日出席在美国纽约君悦酒店召开的2017年摩根士丹利全球医疗保健大会。
From September 11 to 13 ,2017, the Ascentage management – Dajun Yang, MD, Ph.D. Chairman & Chief Executive Officer, Hanzhong Li, MD, Ph.D. Chief Financial Officer, and LuZhang, Associate Director of Business Development, will attend the Morgan Stanley Global Healthcare Conference 2017 at Grand Hyatt Hotel in New York City.
关于亚盛医药
亚盛医药是一家立足中国、面向全球的原创新药研发企业，在肿瘤、乙肝及与衰老相关的疾病治疗领域已成功布局，尤其在细胞凋亡和自噬双通道调控抗肿瘤药物领域的研发领先全球，所有在研项目均为新化合物结构的原创1类新药，填补国内空白，并旨在进军国际高端医药市场。公司在基于靶向蛋白结构的药物设计与优化领域形成了多项核心技术，拥有一百多项国际发明专利。截止目前，亚盛医药已有6个产品进入美国、澳洲和中国临床I-II期阶段。
Ascentage Pharma is a China-based,global,clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs incancers, hepatitis B and aging-related diseases. Ascentage has world-leading proprietary Protein-Protein Interaction drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programsin preclinical stages.
亚盛医药的研发产品管线包括细胞凋亡路径关键蛋白的抑制剂，通过抑制BCL-2/ Bcl-xL，IAP和MDM2-p53等，重启肿瘤细胞的凋亡程序；第二代和第三代的针对癌症治疗中出现的激酶突变体的抑制剂；与肿瘤治疗的有密切相关性的表观遗传学靶点的抑制剂等。
The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP,Bcl-2/Bcl-xL and MDM2-p53, that restore a tumor cell's programmed cell death program; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics.
更多详情请访问亚盛医药官网
For more information, please visit:
www.ascentagepharma.com.
长按关注，亚盛医药最新动态尽在掌握！